文献速递泌尿生殖MR

3-T多参数MRI联合磁共振引导下活检检测既往经直肠超声引导活检阴性后的临床显著前列腺癌

3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
PubMed 文献 · AJR Am J Roentgenol · 2020-07-08

本研究回顾性纳入79例既往经直肠超声引导活检阴性、MRI阳性(PI-RADS≥3)的患者,行3-T磁共振引导下活检,临床显著前列腺癌检出率为38%。PI-RADSv2.1评分是临床显著前列腺癌检出的强预测因子(OR 3.97)。

要点

  • PI-RADSv2.1评分是临床显著前列腺癌检出的强预测因子(OR 3.97,95%CI 1.93-7.47)。
  • PI-RADSv2.1 3、4、5分病灶的前列腺癌检出率分别为18.4%、65.2%、87.5%。
  • 7例PI-RADSv2.1 3分临床显著前列腺癌中6例PSA密度>0.10 ng/mL/cc。

关键影像表现/征象

  • 磁共振引导下活检检出前列腺癌36例(45.6%),其中30例(83.3%)为临床显著前列腺癌。
  • 2个良性移行区靶病灶从PI-RADSv2 3分降级为PI-RADSv2.1 2分。

诊断标准与关键数值

  • 临床显著前列腺癌定义为Gleason评分3+4或更高。
  • PI-RADSv2.1 3、4、5分病灶的前列腺癌检出率分别为18.4%(7/38)、65.2%(15/23)、87.5%(14/16)。
  • 上述检出病例中临床显著前列腺癌分别为85.7%(6/7)、86.7%(13/15)、78.6%(11/14)。
  • PI-RADSv2.1评分预测临床显著前列腺癌检出的OR为3.97(95%CI 1.93-7.47)。

临床应用与阅片要点

  • 作者认为,PI-RADSv2.1 4或5分病灶患者及PI-RADSv2.1 3分且PSA密度≥0.10 ng/mL/cc的患者可能从磁共振引导下活检中获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this study was to evaluate the rate of detection of clinically significant prostate cancer (csPCa), as assessed on the basis of Prostate Imaging Reporting and Data System version 2.1 (PI-RADSv2.1) guidelines, using 3-T in-bore MR-guided biopsy (MRGB) for a cohort of patients suspected of having csPCa despite having a history of recent negative transrectal ultrasound-guided biopsy results. MATERIALS AND METHODS. The cohort in this retrospective, single-center study was derived from a database of 330 patients who underwent multiparametric MRI (mpMRI) followed by in-bore transrectal 3-T MRGB. Seventy-nine patients (mean [± SD] age, 64.1 ± 8.6 years) with prior negative transrectal ultrasound-guided biopsy results and positive pre-MRGB mpMRI results (PI-RADS score ≥ 3) composed the final cohort. The rate of detection of PCa and csPCa (the latter of which was defined by a Gleason score of 3 + 4 or higher) was stratified according to updated PI-RADSv2.1 assessment. RESULTS. MRGB detected PCa in 36 patients (45.6%), 30 (83.3%) of whom had csPCa. The PI-RADSv2.1 score was a strong predictor (odds ratio, 3.97; 95% CI, 1.93-7.47) of csPCa detection. We found two benign transition zone target lesions that were downgraded from PI-RADSv2 category 3 to PI-RADSv2.1 category 2. PCa was detected in 18.4% (7/38), 65.2% (15/23), and 87.5% (14/16) of individuals with PI-RADSv2.1 category 3, 4, and 5 lesions, respectively, with 85.7% (6/7), 86.7% (13/15), and 78.6% (11/14) of these cases found to be csPCa, respectively. Of the seven PI-RADSv2.1 category 3 csPCa lesions, six had prostate-specific antigen density greater than 0.10 ng/mL/cc. CONCLUSION. With the use of 3-T in-bore MRGB, csPCa was detected in 38% of individuals with prior negative transrectal ultrasound-guided biopsy results. PI-RADSv2.1 was a strong predictor of csPCa detection. On the basis of our results, patients with PI-RADSv2.1 category 4 or 5 lesions and patients with PI-RADSv2.1 category 3 lesions and a prostate-specific antigen density greater than or equal to 0.10 ng/mL/cc may benefit from in-bore MRGB.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Hosseiny M, Shakeri S, Felker ER, et al. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy. AJR Am J Roentgenol. 2020. PMID: 32755166. doi:10.2214/AJR.19.22455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。